New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
08:49 EDTOMEDOncoMed to present data for Notch1 program
OncoMed Pharmaceuticals will present new data at the upcoming 19th European Hematology Association Congress related to the company's anti-Notch1 clinical-stage program. At the EHA Congress, OncoMed will present the first data for its proprietary Next Generation DNA Sequencing assay developed with MolecularMD to identify Notch1 mutation status in patients with certain hematologic malignancies. OncoMed is currently conducting two separate Phase 1 clinical studies of its Notch1 targeting antibody in patients with certain advanced solid and hematologic tumors, respectively.
News For OMED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
08:17 EDTOMEDOncoMed presents data from tarextumab, demcizumab trials
OncoMed Pharmaceuticals presented data in two posters highlighting the company's translational research and biomarker efforts for its tarextumab and demcizumab clinical programs Jakob Dupont, M.D., OncoMed's Chief Medical Officer, stated, "The data from the Phase 1b clinical trials of tarextumab and demcizumab demonstrate that our preclinical understanding of on-target drug activity and predictive biomarkers is being validated in the clinic as we study actual patient tumor samples. In the ALPINE Phase 1b study in advanced pancreatic cancer, we see clear evidence that tarextumab modulates the Notch cancer stem cell pathway in patient samples and that there is a potential association between tumors that show higher levels of Notch3 gene expression and best responses to tarextumab treatment. In the demcizumab poster presentation, a case study is described from our Phase 1b trial in pancreatic cancer in which the tumor response to treatment that occurred in the clinic correlates with what we observe using patient-derived xenograft models. This may provide insights into the development of potential biomarkers of response to demcizumab treatment in that program."
November 19, 2014
07:54 EDTOMEDOncoMed presents biomarker-focused clinical data from Anti-Notch1 Phase 1a trial
Subscribe for More Information
November 12, 2014
07:53 EDTOMEDLeerink to hold a tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use